STOCK TITAN

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Allurion Technologies (NYSE: ALUR) presented significant data at Obesity Week 2024, showcasing results from their largest real-world study involving 19,428 patients across 72 countries. The study demonstrated an average weight reduction of 12.2% after four months using the Allurion Program. Additionally, a second study revealed that patients who previously had unsuccessful results with liraglutide achieved an average 17.6% weight reduction after four months on the Allurion Program. This group included patients where 55% had no weight loss and 45% had less than 5% weight loss with GLP-1 medications.

Allurion Technologies (NYSE: ALUR) ha presentato dati significativi durante l'Obesity Week 2024, mostrando i risultati del loro studio reale più grande che ha coinvolto 19.428 pazienti in 72 paesi. Lo studio ha dimostrato una riduzione media del peso del 12,2% dopo quattro mesi utilizzando il Programma Allurion. Inoltre, un secondo studio ha rivelato che i pazienti che in precedenza avevano ottenuto risultati negativi con liraglutide hanno raggiunto una riduzione media del peso del 17,6% dopo quattro mesi con il Programma Allurion. Questo gruppo includeva pazienti in cui il 55% non aveva perso peso e il 45% aveva avuto una perdita di peso inferiore al 5% con i farmaci GLP-1.

Allurion Technologies (NYSE: ALUR) presentó datos significativos en la Semana de la Obesidad 2024, mostrando los resultados de su estudio del mundo real más grande, que involucró a 19,428 pacientes en 72 países. El estudio demostró una reducción media de peso del 12.2% después de cuatro meses utilizando el Programa Allurion. Además, un segundo estudio reveló que los pacientes que anteriormente habían tenido resultados insatisfactorios con liraglutida lograron una reducción media de peso del 17.6% después de cuatro meses en el Programa Allurion. Este grupo incluía pacientes en los que el 55% no había perdido peso y el 45% había tenido una pérdida de peso de menos del 5% con medicamentos GLP-1.

Allurion Technologies (NYSE: ALUR)는 2024 비만 주간에서 중요한 데이터를 발표하며 72개국의 19,428명 환자를 대상으로 한 최대 규모의 실제 연구 결과를 선보였습니다. 이 연구는 Allurion 프로그램을 사용한 후 4개월 동안 평균 12.2%의 체중 감소를 보여주었습니다. 또한, 두 번째 연구에서 리라글루타이드로 이전에 성공적인 결과를 얻지 못한 환자들이 Allurion 프로그램을 통해 4개월 후 평균 17.6%의 체중 감소를 달성했다고 밝혔습니다. 이 그룹은 55%가 체중 감소가 없었고 45%가 GLP-1 약물로 5% 미만의 체중 감소를 경험한 환자들로 구성되었습니다.

Allurion Technologies (NYSE: ALUR) a présenté des données significatives lors de la Semaine de l'Obésité 2024, mettant en avant les résultats de leur plus grande étude en conditions réelles impliquant 19 428 patients dans 72 pays. L'étude a révélé une réduction moyenne de poids de 12,2% après quatre mois d'utilisation du Programme Allurion. De plus, une deuxième étude a révélé que les patients qui avaient précédemment obtenu des résultats infructueux avec le liraglutide ont atteint une réduction de poids moyenne de 17,6% après quatre mois avec le Programme Allurion. Ce groupe comprenait des patients dont 55% n'avaient pas perdu de poids et 45% avaient moins de 5% de perte de poids avec des médicaments GLP-1.

Allurion Technologies (NYSE: ALUR) präsentierte bedeutende Daten während der Obesity Week 2024 und zeigte die Ergebnisse ihrer größten Real-World-Studie mit 19.428 Patienten aus 72 Ländern. Die Studie zeigte eine durchschnittliche Gewichtsreduktion von 12,2% nach vier Monaten unter Verwendung des Allurion-Programms. Darüber hinaus ergab eine zweite Studie, dass Patienten, die zuvor mit Liraglutid keine erfolgreichen Ergebnisse erzielt hatten, nach vier Monaten im Allurion-Programm eine durchschnittliche 17,6% Gewichtsreduktion erreichten. Diese Gruppe umfasste Patienten, von denen 55% keinen Gewichtsverlust und 45% weniger als 5% Gewichtsverlust mit GLP-1-Medikamenten hatten.

Positive
  • Large-scale real-world study shows consistent 12.2% average weight reduction across 19,428 patients
  • Demonstrated 17.6% weight reduction in patients who failed GLP-1 treatment
  • Program shows effectiveness across 72 countries, indicating strong market penetration
Negative
  • None.

Insights

The real-world data from 19,428 patients across 72 countries demonstrates robust validation of the Allurion Program's effectiveness, showing an average 12.2% total body weight loss in just 4 months. This positions Allurion competitively in the weight loss market, especially against GLP-1 medications which typically require longer treatment periods.

The second study's findings on GLP-1 non-responders are particularly significant. Patients who failed to achieve meaningful results with liraglutide attained an impressive 17.6% weight reduction with the Allurion Program. This suggests a valuable alternative treatment pathway for the substantial portion of patients who don't respond adequately to GLP-1s, potentially expanding Allurion's market opportunity in the growing obesity treatment sector.

These clinical results strengthen Allurion's market position in the competitive weight loss industry. The large-scale real-world evidence spanning 72 countries provides credibility and could accelerate insurance coverage and market adoption. The successful treatment of GLP-1 non-responders is particularly strategic, as it positions Allurion as a complementary rather than competing solution to popular GLP-1s like Wegovy and Ozempic, potentially opening new revenue streams and partnership opportunities.

19,428 patients treated with the Allurion Program across 72 countries lost an average of 12.2% of total body weight

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2024, the annual meeting of The Obesity Society.

The first abstract comprises outcomes data from Allurion’s largest real-world cohort on record. The data, gathered from 19,428 patients across 72 countries treated between 2018 and 2023 with the Allurion Program with results tracked digitally through the Allurion Virtual Care Suite, reveals consistent and significant weight loss outcomes with an average weight reduction of 12.2% at four months across the population.

“While a number of clinical trials have been conducted on intragastric balloons, there has been a persistent lack of large-scale, real-world outcomes data,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “These data demonstrate that the Allurion Program can consistently and repeatedly achieve clinically meaningful weight loss in a vast and diverse population, adding to the data that have already been published on the Allurion Program in over 26 peer-reviewed publications.”

The second abstract reports on outcomes of the Allurion Program for 27 patients previously treated with liraglutide who did not respond to their GLP-1 treatment. 55% had no weight loss and 45% had weight loss of less than 5% with GLP-1 medications. The study showed that these patients achieved an average weight reduction of 17.6% after just four months on the Allurion Program.

“Clinical studies indicate that, depending on the GLP-1 medication, more than a third of patients do not achieve over 10% TBWL at one year, with lower real-world response rates1. In addition, it can take 3 months to determine whether treatment is working,” said Dr. Ram Chuttani, Chief Medical Officer and Founding Partner of Allurion. “Our findings suggest that the Allurion Program can be a game-changer for patients who do not respond to GLP-1 treatments,” he added.

Sources: 1. Gasoyan H, Pfoh ER, Schulte R, Le P, Butsch WS, Rothberg MB. One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice. JAMA Netw Open. 2024;7(9):e2433326. Published 2024 Sep 3. doi:10.1001/jamanetworkopen.2024.33326

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the ability of the Allurion Program, which combines the Allurion Balloon with ongoing virtual guidance and support, to improve patient and clinical outcomes, including outcome improvements over time and as compared to other weight loss treatments. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the VCS platform, and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

Global Media

Cedric Damour

PR Manager

+33 7 84 21 02 20

cdamour@allurion.com

Investor Contact

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Allurion Technologies, Inc.

FAQ

What was the average weight loss percentage in Allurion's (ALUR) 2024 real-world study?

The study showed patients achieved an average weight reduction of 12.2% after four months on the Allurion Program.

How many patients were included in Allurion's (ALUR) largest real-world study presented at Obesity Week 2024?

The study included 19,428 patients across 72 countries, making it Allurion's largest real-world cohort on record.

What were the results of Allurion's (ALUR) program for patients who failed GLP-1 treatment?

Patients who previously failed GLP-1 treatment achieved an average weight reduction of 17.6% after four months on the Allurion Program.

Allurion Technologies, Inc.

NYSE:ALUR

ALUR Rankings

ALUR Latest News

ALUR Stock Data

44.56M
64.39M
24.61%
33.9%
1.02%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NATICK